Results 141 to 150 of about 3,717,417 (345)

Akt Promotes Post-Irradiation Survival of Human Tumor Cells through Initiation, Progression, and Termination of DNA-PKcs–Dependent DNA Double-Strand Break Repair [PDF]

, 2012
Mahmoud Toulany, Kyung Jong Lee, Kazi R. Fattah, Yu‐Fen Lin, B. Fehrenbacher, Martin Schaller, Benjamin P. Chen, David J. Chen, H. Peter Rodemann   +8 more
openalex   +1 more source

The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity

, 2023
Patricia Ho, Johannes C. Melms, Meri Rogava, Chris J. Frangieh, Joanna Poźniak, Shivem B. Shah, Zachary Walsh, Oleksandr Kyrysyuk, Amit Dipak Amin, Lindsay Caprio, Benjamin T. Fullerton, Rajesh K. Soni, Casey R. Ager, Jana Biermann, Yi‐Ping Wang, Mohsen Khosravi‐Maharlooei, Giorgia Zanetti, Michael Mu, Hijab Fatima, Emily K. Moore, Neil Vasan, Samuel F. Bakhoum, Steven L. Reiner, Chantale Bernatchez, Megan Sykes, Emily M. Mace, Kai W. Wucherpfennig, Dirk Schadendorf, Oliver Bechter, Parin Shah, Gary K. Schwartz, Jean‐Christophe Marine, Benjamin Izar   +32 more
openalex   +2 more sources

Inhibiting stearoyl‐CoA desaturase suppresses bone metastatic prostate cancer by modulating cellular stress, mTOR signaling, and DNA damage response

FEBS Letters, EarlyView.
Bone metastasis in prostate cancer (PCa) patients is a clinical hurdle due to the poor understanding of the supportive bone microenvironment. Here, we identify stearoyl‐CoA desaturase (SCD) as a tumor‐promoting enzyme and potential therapeutic target in bone metastatic PCa.
Alexis Wilson, Mackenzie K Herroon, Shane Mecca, Laimar C Garmo, Jacob Lindquist, Shrila Rajendran, Steve M. Patrick, Izabela Podgorski   +7 more
wiley   +1 more source

Cancer biomarkers, and novel techniques for detection [PDF]

, 2017
Technologies for early detection of tumors is critical for better therapy outcome and overall change in cancer survival. These assays must be capable of detecting tumors at early stages in order to prevent metastasis of the tumor and help reduce ...
Jamal, Tameem
core  

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source

Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors [PDF]

, 2009
Hemant Sarin, Ariel S Kanevsky, Haitao Wu, Alioscka A. Sousa, Colin M. Wilson, Maria A. Aronova, Gary L. Griffiths, Richard D. Leapman, Howard Q. Vo   +8 more
openalex   +1 more source

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

Molecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu   +5 more
wiley   +1 more source

alimentaci´on parenteral en el neoplasma de esófago

Cirugía del Uruguay, 1980
Se analizan 31 casos de pacientes portadores de neoplasma de esófago que recibieron alimentación parentera1 durante su internación en sala de Cirugía General. No se registraron muertes ni complicaciones serias debTdas a la técnica.
Ricardo Voelker, Oscar Balboa, Ana Lerena   +2 more
doaj  

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Enhanced Anti-tumor Activity by the Combination of the Natural Compounds (−)-Epigallocatechin-3-gallate and Luteolin [PDF]

, 2010
A.R.M. Ruhul Amin, Dongsheng Wang, Hongzheng Zhang, Shifang Peng, Hyung Ju C. Shin, Johann C. Brandes, Mourad Tighiouart, Fadlo R. Khuri, Zhuo Georgia Chen, Dong M. Shin   +9 more
openalex   +1 more source